Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPRX Catalyst Pharmaceuticals	$24.89 +1.3%	$23.57	$14.75 ▼ $26.16	$3.04B	0.7	1.11 million shs	2.08 million shs
PRAX Praxis Precision Medicines	$38.58 +0.3%	$35.63	$26.70 ▼ $91.83	$785.84M	2.65	384,791 shs	342,490 shs
VKTX Viking Therapeutics	$26.98 -4.2%	$25.76	$18.92 ▼ $81.73	$3.03B	0.75	4.07 million shs	2.84 million shs
XENE Xenon Pharmaceuticals	$28.72 -1.1%	$33.00	$26.74 ▼ $46.00	$2.20B	1.21	540,340 shs	2.46 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPRX Catalyst Pharmaceuticals	0.00%	+1.63%	+0.20%	+11.51%	+53.93%
PRAX Praxis Precision Medicines	0.00%	+2.74%	-4.13%	+14.99%	-18.71%
VKTX Viking Therapeutics	0.00%	0.00%	-8.11%	+4.98%	-56.67%
XENE Xenon Pharmaceuticals	0.00%	-3.46%	-24.97%	-19.75%	-24.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CPRX Catalyst Pharmaceuticals	4.8825 of 5 stars	3.6	3.0	3.9	4.2	3.3	2.5
PRAX Praxis Precision Medicines	1.9228 of 5 stars	3.4	2.0	0.0	2.9	1.7	0.0
VKTX Viking Therapeutics	4.5295 of 5 stars	4.5	2.0	4.7	2.4	3.3	0.0
XENE Xenon Pharmaceuticals	3.5552 of 5 stars	4.5	4.0	0.0	3.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CPRX Catalyst Pharmaceuticals	3.13	Buy	$32.29	29.71% Upside
PRAX Praxis Precision Medicines	2.80	Moderate Buy	$116.50	201.97% Upside
VKTX Viking Therapeutics	3.00	Buy	$87.15	223.03% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$54.82	90.87% Upside

Current Analyst Ratings Breakdown

Latest PRAX, VKTX, XENE, and CPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	XENE Xenon Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$55.00
5/13/2025	XENE Xenon Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $47.00
5/13/2025	XENE Xenon Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$58.00 ➝ $55.00
5/13/2025	XENE Xenon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$53.00 ➝ $53.00
5/13/2025	XENE Xenon Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00
5/13/2025	XENE Xenon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $55.00
5/7/2025	PRAX Praxis Precision Medicines	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
5/7/2025	XENE Xenon Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$55.00
5/5/2025	PRAX Praxis Precision Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$26.00 ➝ $28.00
5/5/2025	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/5/2025	XENE Xenon Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CPRX Catalyst Pharmaceuticals	$534.65M	5.68	$2.32 per share	10.72	$3.30 per share	7.54
PRAX Praxis Precision Medicines	$8.12M	96.75	N/A	N/A	$7.92 per share	4.87
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$3.48 per share	N/A
XENE Xenon Pharmaceuticals	$7.50M	293.84	N/A	N/A	$14.18 per share	2.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CPRX Catalyst Pharmaceuticals	$71.41M	$1.57	21.09	11.69	3.31	31.01%	40.79%	34.87%	8/6/2025 (Estimated)
PRAX Praxis Precision Medicines	-$123.28M	-$10.72	N/A	N/A	N/A	-9,409.22%	-54.86%	-50.52%	8/12/2025 (Estimated)
VKTX Viking Therapeutics	-$109.96M	-$1.15	N/A	N/A	N/A	N/A	-11.93%	-11.57%	7/23/2025 (Estimated)
XENE Xenon Pharmaceuticals	-$182.39M	-$3.23	N/A	N/A	N/A	N/A	-24.69%	-23.68%	8/14/2025 (Estimated)

Latest PRAX, VKTX, XENE, and CPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	XENE Xenon Pharmaceuticals	-$0.90	-$0.83	+$0.07	-$0.83	$1.64 million	$7.50 million
5/2/2025	Q1 2025	PRAX Praxis Precision Medicines	-$3.20	-$3.29	-$0.09	-$3.29	$0.20 million	N/A
4/23/2025	Q1 2025	VKTX Viking Therapeutics	-$0.31	-$0.41	-$0.10	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CPRX Catalyst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CPRX Catalyst Pharmaceuticals	N/A	5.11	4.92
PRAX Praxis Precision Medicines	N/A	10.96	10.96
VKTX Viking Therapeutics	N/A	36.47	36.47
XENE Xenon Pharmaceuticals	N/A	22.21	22.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CPRX Catalyst Pharmaceuticals	79.22%
PRAX Praxis Precision Medicines	67.84%
VKTX Viking Therapeutics	76.03%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
CPRX Catalyst Pharmaceuticals	10.40%
PRAX Praxis Precision Medicines	2.70%
VKTX Viking Therapeutics	4.10%
XENE Xenon Pharmaceuticals	5.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CPRX Catalyst Pharmaceuticals	80	121.98 million	106.15 million	Optionable
PRAX Praxis Precision Medicines	110	20.37 million	18.14 million	Optionable
VKTX Viking Therapeutics	20	112.31 million	106.20 million	Optionable
XENE Xenon Pharmaceuticals	210	76.73 million	72.03 million	Optionable

PRAX, VKTX, XENE, and CPRX Headlines

Recent News About These Companies

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

June 2 at 4:23 AM | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Bank of America Corp DE

May 31 at 3:14 AM | marketbeat.com

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 30 at 4:01 PM | globenewswire.com

Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE)

May 30 at 2:31 AM | marketbeat.com

Ameriprise Financial Inc. Increases Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 28, 2025 | marketbeat.com

Woodline Partners LP Makes New $1.57 Million Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 27, 2025 | marketbeat.com

Two Sigma Investments LP Increases Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 27, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Position Lifted by Millennium Management LLC

May 26, 2025 | marketbeat.com

Northern Trust Corp Raises Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 26, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Acquired by Two Sigma Advisers LP

May 25, 2025 | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Lowered by StockNews.com

May 23, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of "Buy" by Brokerages

May 23, 2025 | marketbeat.com

Fair Value analysis proves accurate as XENE drops 37% from February 2024 peak

May 21, 2025 | investing.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Vestal Point Capital LP

May 21, 2025 | marketbeat.com

D. E. Shaw & Co. Inc. Sells 117,919 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 21, 2025 | marketbeat.com

Ensign Peak Advisors Inc Sells 136,970 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 19, 2025 | marketbeat.com

Leerink Partnrs Issues Optimistic Forecast for XENE Earnings

May 18, 2025 | marketbeat.com

Sphera Funds Management LTD. Acquires Shares of 52,097 Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 18, 2025 | marketbeat.com

Polar Capital Holdings Plc Increases Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 17, 2025 | marketbeat.com

HC Wainwright Issues Positive Outlook for XENE Earnings

May 17, 2025 | marketbeat.com

Traders Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)

May 17, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAX, VKTX, XENE, and CPRX Company Descriptions

Catalyst Pharmaceuticals NASDAQ:CPRX

$24.89 +0.31 (+1.26%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$24.96 +0.07 (+0.28%)

As of 04:01 AM Eastern

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Praxis Precision Medicines NASDAQ:PRAX

$38.58 +0.13 (+0.34%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$38.55 -0.03 (-0.08%)

As of 03:59 AM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Viking Therapeutics NASDAQ:VKTX

$26.98 -1.18 (-4.19%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$26.80 -0.18 (-0.67%)

As of 03:59 AM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Xenon Pharmaceuticals NASDAQ:XENE

$28.72 -0.32 (-1.10%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$28.85 +0.13 (+0.45%)

As of 03:59 AM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time